The American Journal of Medicine
Volume 116, Issue 6, Supplement 1 , Pages 26-30 , 22 March 2004

Risk assessment and strategies to achieve lipid goals: lessons from real-world clinical practice

  • Herbert Schuster, MD

      Affiliations

    • INFOGEN, Berlin, Germany
    • Corresponding Author InformationRequests for reprints should be addressed to Herbert Schuster, MD, INFOGEN, Xantener Strasse 10, 10707 Berlin, Germany.

References 

  1. Fedder DO, Koro CE, L'Italien GJ. New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy (projected impact on the size, sex, and age distribution of the treatment-eligible population). Circulation. 2002;105:152–156
  2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults . Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  3. Assmann G. Pro and con (high-density lipoprotein, triglycerides, and other lipid subfractions are the future of lipid management). Am J Cardiol. 2001;878(suppl 5A):2B–7B
  4. Criqui MH, Langer RD, Fronek A, et al.  Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326:381–386
  5. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease (a meta-analysis of randomized controlled trials). JAMA. 1999;282:2340–2346
  6. Williams RR, Hunt SC, Schumacher MC, et al.  Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol. 1993;72:171–176
  7. Goldstein JL, Brown MS. The LDL receptor defect in familial hypercholesterolemia (implications for pathogenesis and therapy). Med Clin North Am. 1982;66:335–362
  8. Rifkind BM, Schucker B, Gordon DJ. When should patients with heterozygous familial hypercholesterolemia be treated?. JAMA. 1999;281:180–181
  9. Brown BG, Zhao XQ, Chait A, et al.  Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583–1592
  10. Wierzbicki AS, Mikhailidis DP, Wray R, et al.  Statin-fibrate combination (therapy for hyperlipidemia: a review). Curr Med Res Opin. 2003;19:155–168

PII: S0002-9343(04)00074-9

doi: 10.1016/j.amjmed.2004.02.008

The American Journal of Medicine
Volume 116, Issue 6, Supplement 1 , Pages 26-30 , 22 March 2004

Article Tools

* Image Usage & Resolution